Miscellaneous metabolic agents are those which do not fall into the existing categories of metabolic agents.
Regular Websites
Miglustat Shows Promise for Cystic Fibrosis
Article discusses this new drug’s progress through the clinical trials, and its promise as of its phase 2 trials on patients with cystic fibrosis. It further details the American Journal of Respiratory Cell and Molecular Biologyn research which shows that daily long-term treatment of the cells of cystic fibrosis with ow doses of miglustat appears to correct the pathological abnormalities and have promise insofar as effective treatment is concerned. - Miglustat Shows Promise for Cystic Fibrosis
http://www.news-medical.net/news/20090721/Miglustat-shows-promise-for-cystic-fibrosis.aspx
Newly Approved Drug Therapies: Orfadin
Consists of basic information about Orfadin, generically known as nitisinone when it was approved and for what uses. as wel ca clinical results and evaluations. Also discusses the mechanism of action, which is that it is a competitive inhibitor of 4-hydroxyphenyl-pyruvate dioxygenase. - Newly Approved Drug Therapies: Orfadin
http://www.centerwatch.com/drug-information/fda-approvals/drug-details.aspx?DrugID=765
Outlines the oral route of sapropterin and its brand names as well as other forms available, drug interactions, and other medical problems. Additionally, it posts details about proper use and dosing. - Sapropterin
http://www.mayoclinic.com/health/drug-information/DR602555